Efficacy of Suprachoroidal versus Intravitreal Triamcinolone Acetonide in Refractory Macular Edema; A Quasi-experimental study

Munazza Aslam; Tehmina Nazir; Rana Intisarul Haq; Asfandyar Asghar; Sana Nadeem; Naila Obaid

doi:10.51253/pafmj.v74i5.10818

Authors

Munazza Aslam Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Pakistan
Tehmina Nazir Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Pakistan
Rana Intisarul Haq Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Pakistan
Asfandyar Asghar Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Pakistan
Sana Nadeem Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Pakistan
Naila Obaid Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.10818

Keywords:

Intravitreal Injections, Macular Edema, Optical Coherence Tomography, Suprachoroidal, Steroids, Triamcinolone Acetonide.

Abstract

Objective: To compare the efficacy of suprachoroidal vs intravitreal triamcinolone acetonide in management of refractory macular edema.

Study Design: Quasi-experimental study

Place and Duration of Study: Ophthalmology Department, Fauji Foundation Hospital, Rawalpindi Pakistan, from Jun to Nov 2022.

Methodology: A total of three hundred and seventy-eight eyes of 189 patients were selected after approval from the Institutional Ethics Review Board. In this study, individuals were divided into two Groups using lottery method: Group-A, received suprachoroidal triamcinolone acetonide and Group-B, received intravitreal triamcinolone acetonide. After intervention, both Groups were followed up at 1 and 3 months. Baseline central macular thickness was noted in each Group. Patients were also observed for complications. Statistical Package for Social Sciences version 23 was utilized for data analysis.

Results: No significant differences were noted between both Groups at baseline Central Macular Thickness (p-value =0.29), However, significant difference was noted at 3-month Central Macular Thickness (p-value as <0.001). Very few compli-cations were observed in both Groups.

Conclusion: This study revealed that both suprachoroidal and intravitreal routes of administering triamcinolone acetonide were equally effective. Significant reduction in Central Macular Thickness and no increase in Intraocular Pressure along with better tolerance for treatment were seen in suprachoroidal route in our research which indicated its safety.

Downloads

Download data is not yet available.

References

Shaikh DD, Kalhoro FA, Shaikh SP, Sheikh RD, Rathi R, Sheikh TA, et al. The frequency of diabetic macular edema and its systemic risk factors: A cross-sectional study. Pak J Med Health Sci 2022; 16(2): 744-749.

https://doi.org/10.53350/pjmhs22162744

Crim N, Velez-Montoya R, Morales-Canton V. Surgical versus medical treatment for diabetic macular edema: a review. Med Hypothesis Discov Innov Ophthalmol 2017; 6(4): 136–142.

McKay KM, Borkar DS, Sevgi DD, Susarla G, Papaliodis GN, Sobrin L. Comparison of modified posterior sub-tenon’s vs trans- septal triamcinolone injection for non-infectious uveitis. Ocul Immunol Inflamm 2020; 4(5): 1–8.

https://doi.org/10.1080/09273948.2019.1698748

Lin Y, Ren X, Chen D. Steroid Treatment in Macular Edema: A Bibliometric Study and Visualization Analysis. Front Pharmacol 2022; 13: 824790. https://doi.org/10.3389/fphar.2022.824790

Shahid MH, Rashid F, Tauqeer S, Ali R, Farooq MT, Aleem N. Comparison of suprachoroidal triamcinolone injection with intravitreal bevacizumab vs intravitreal bevacizumab only in treatment of refractory diabetic macular edema. Pak J Med Health Sci 2022; 16(6): 301-303.

https://doi.org/10.53350/pjmhs22166301

Wykoff CC, Khurana RN, Lampen SIR, Noronha G, Brown DM, Ou WC, et al. Suprachoroidal triamcinolone acetonide for diabetic macular edema: The HULK Trial. Ophthalmol Retina 2018; 2(8): 874-877.

Yeh S, Kurup SK, Wang RC, Foster CS, Noronha G, Nguyen QD, et al. Suprachoroidal injection of triamcinolone acetonidefor macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina 2019; 39(10): 1880-1888.

https://doi.org/10.1097/IAE.0000000000002279

Yeh S, Khurana RN, Shah M, Henry CR, Wang RC, Kissner JM, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology 2020; 127(7): 948-955.

https://doi.org/10.1016/j.ophtha.2020.01.006

Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmol Retina 2018; 2(4): 320-328.

https://doi.org/10.1016/j.oret.2017.07.013

Tayyab H, Ahmed CN, Sadiq MAA. Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pak J Med Sci 2020; 36(2): 42-47.

https://doi.org/10.12669/pjms.36.2.1194

Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidal injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol 2019; 97(5): 460–472. https://doi.org/10.1111/aos.14042

Ghoraba HH, Leila M, Elgouhary SM, Elgemai EEM, Abdelfattah HM, Ghoraba HH, et al. Safety of high- dose intravitreal triamcinolone acetonide as low- cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. Clin Ophthalmol 2018; 12: 2383-23891.

Zakaria YG, Salman AG, Said AMA, Abdelatif MK. Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema. Clin Ophthalmol 2022; 16: 733-746.

Hanif J, Iqbal K, Perveen F. Safety and efficacy of suprachoroidal injection of triamcinolone in treating macular edema secondary to noninfectious uveitis. Cureus 2021; 13(11): e20038.

https://doi.org/10.7759/cureus.20038

Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol 2013; 7: 1109-1144.

Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011; 118(10): 1916-1926. https://doi.org/10.1016/j.ophtha.2011.07.027

Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, et al. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol 2011; 152(6): 1044-1052.

https://doi.org/10.1016/j.ajo.2011.05.028

Ali BM, Azmeh AM, Alhalabi NM. Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study. BMC Ophthalmol 2023; 23(1): 60.

https://doi.org/10.1186/s12886-023-02808-5